Literature DB >> 22385229

Renal Fanconi syndrome as a cause of chronic kidney disease in patients with monoclonal gammopathy of undetermined significance: partially reversed renal function by high-dose dexamethasone with bortezomib.

Yuki Nishida, Kan-ichi Iwama, Masayuki Yamakura, Masami Takeuchi, Kosei Matsue.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22385229     DOI: 10.3109/10428194.2012.671483

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  4 in total

1.  Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients.

Authors:  M Vignon; V Javaugue; M P Alexander; K El-Karoui; A Karras; D Roos-Weil; B Royer; B Asli; B Knebelmann; G Touchard; A Jaccard; B Arnulf; F Bridoux; N Leung; J P Fermand
Journal:  Leukemia       Date:  2016-07-20       Impact factor: 11.528

2.  Light Chain Proximal Tubulopathy: Clinical and Pathologic Characteristics in the Modern Treatment Era.

Authors:  Michael B Stokes; Anthony M Valeri; Leal Herlitz; Abdullah M Khan; David S Siegel; Glen S Markowitz; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2015-09-15       Impact factor: 10.121

3.  Clinicopathological characteristics and long-term prognosis of monoclonal immunoglobulin light chain associated Fanconi syndrome.

Authors:  Zhixin Chen; Jiaying Li; Xiaoxiao Shi; Ying Wang; Peng Xia; Wei Ye; Wenling Ye; Yan Qin; Hang Li; Mingxi Li; Xuemei Li; Yubing Wen; Limeng Chen
Journal:  Ther Adv Hematol       Date:  2021-01-30

Review 4.  Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma.

Authors:  Michael H Tomasson; Mahmoud Ali; Vanessa De Oliveira; Qian Xiao; Yogesh Jethava; Fenghuang Zhan; Adam M Fitzsimmons; Melissa L Bates
Journal:  Int J Mol Sci       Date:  2018-11-16       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.